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In Brief
Intravital microscopy studies have
recently revealed that dendritic cells
(DCs) migrating to draining lymph nodes
actively crawl within afferent lymphatic
capillaries. Here, Russo et al. provide
evidence that an intraluminal CCL21
gradient, which is deposited by lymph
flow, guides DCs migrating within
capillaries in the downstream direction of
the collecting lymphatic vessels.
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To induce adaptive immunity, dendritic cells (DCs)
migrate through afferent lymphatic vessels (LVs) to
draining lymph nodes (dLNs). This process occurs
in several consecutive steps. Upon entry into
lymphatic capillaries, DCs first actively crawl into
downstream collecting vessels. From there, they
are next passively and rapidly transported to the
dLN by lymph flow. Here, we describe a role for the
chemokine CCL21 in intralymphatic DC crawling.
Performing time-lapse imaging in murine skin, we
found that blockade of CCL21—but not the absence
of lymph flow—completely abolished DC migration
from capillaries toward collecting vessels and
reduced the ability of intralymphatic DCs to emigrate
from skin. Moreover, we found that in vitro low
laminar flow established a CCL21 gradient along
lymphatic endothelial monolayers, thereby inducing
downstream-directed DC migration. These findings
reveal a role for intralymphatic CCL21 in promoting
DC trafficking to dLNs, through the formation of a
flow-induced gradient.
INTRODUCTION
Dendritic cell (DC) migration from peripheral tissues through
afferent lymphatic vessels (LVs) to draining lymph nodes
(dLNs) is essential for sustaining peripheral tolerance and for
promoting immune responses against pathogens or vaccines
(Fo¨rster et al., 2012; Ueno et al., 2007). Over the past 15 years,
several molecular mediators of DC migration into LVs have
been identified (Fo¨rster et al., 2012; Teijeira et al., 2014). Above
all, the prominent role of the chemokine CCL21, which is consti-
tutively expressed by LVs, and its DC-expressed receptor, the
CC-chemokine receptor 7 (CCR7), in DC trafficking to dLNs
has been recognized (Fo¨rster et al., 1999; Saeki et al., 1999).Cell RRecently, time-lapse imaging studies have provided further,
cellular insights into DCmigration through afferent LVs. In partic-
ular, these studies have revealed that DC trafficking through
afferent LVs occurs in distinct steps. In a first step, CCR7-ex-
pressing DCs are guided toward LVs by haptotactic migration
along the immobilized peri-lymphatic CCL21 gradient (Weber
et al., 2013). Once in proximity of lymphatic capillaries, CCL21
also supports the docking of DCs onto lymphatic endothelial
cells (LECs) (Tal et al., 2011). Subsequently, DCs enter into
lymphatic capillaries by squeezing through characteristic flaps
that are formed between neighboring oak-leaf-shaped LECs
(Baluk et al., 2007; Pflicke and Sixt, 2009). Once within the ves-
sels, DCs actively crawl through the capillaries (Nitschke´ et al.,
2012; Sen et al., 2010; Tal et al., 2011). Intriguingly, DCs do not
migrate completely directionally from capillaries into the down-
stream collecting LVs. Rather, they display a semi-directed
patrolling behavior, as they frequently turn within capillaries
and migrate for some time in the opposite direction of drainage
(Nitschke´ et al., 2012; Tal et al., 2011). The final step, namely,
passive transport by lymph flow, is only observed within down-
stream-located collecting LVs (Nitschke´ et al., 2012; Tal et al.,
2011), likely because lymph flow in capillaries (in the order of
1–30 mm/s [Berk et al., 1996; Swartz et al., 1996]) is too low to
support passive transport. Nevertheless, efficient propagation
of DCs from peripheral tissues to dLNs depends on a rapid
transport phase by flow, since the migratory speed of DCs
within capillaries (5–8 mm/min [Nitschke´ et al., 2012; Tal et al.,
2011]) is too slow to explain how DCs could arrive in dLNs within
6 hr to 1 day after onset of migration (Allan et al., 2006; Kissenp-
fennig et al., 2005). These considerations imply that active
migration of DCs from lymphatic capillaries into the collecting
vessels represents a rate-limiting step in the propagation of
DCs to the dLN and therefore prompted us to further investigate
the signals that control this process. Surprisingly, we found
that DCs within lymphatic capillaries of explanted skin continued
to preferentially migrate in the downstream direction, suggesting
that—rather than lymph flow—chemotactic signals deposited in
the vessel lumen might account for this behavior. In support of
this hypothesis, we found that downstream-directed migrationeports 14, 1723–1734, February 23, 2016 ª2016 The Authors 1723
of DCs within lymphatic capillaries and emigration of intralym-
phatic DCs through the lymphatic network was dependent on
CCL21/CCR7 signaling. Moreover, in in vitro flow chamber
experiments, low but not high laminar flow induced the forma-
tion of a functional CCL21 gradient along LEC monolayers,
suggesting a role for lymph flow in the establishment of a
haptotactic intraluminal CCL21 gradient. The latter directs
active migration of DCs from capillaries toward the collecting
vessels, to enable their subsequent rapid transport to the dLN
by lymph flow.
RESULTS
Preferential Migration of DCs within Lymphatic
Capillaries in the Downstream Direction Occurs
Independently of Lymph Flow
We have recently established an intravital microscopy (IVM)
model in which adoptively transferred, yellow fluorescent protein
(YFP)-expressing DCs are imaged in the ear skin of VE-cadherin-
Cre 3 RFP mice (Nitschke´ et al., 2012) (Figure 1A). Using this
model, we observed that DCs within the capillaries migrated in
a semi-directed manner toward the collecting vessels (Nitschke´
et al., 2012) (Movies S1, S2, and S3). To accurately quantify
directedness of cell migration within LVs, we established a new
parameter: the downstream migration index (DMI). The DMI is
based on the optimal migratory path (OMP), the shortest path
along a vessel midline that an intralymphatic DC can migrate
(Figure 1B). To calculate the DMI, the OMP is divided by the total
path length (TPL). Moreover, a positive or negative value is as-
signed to the product, depending on whether net migration
occurred in the downstream or upstream direction of the LV
tree, respectively (Figure 1B). In agreement with our qualitative
assessment, the majority but not all adoptively transferred intra-
lymphatic DCs displayed a positive DMI, indicating semi-
directed migration (Figures 1C and 1D). Blood flow was recently
shown to impact the directionality of leukocyte crawling within
blood vessels (BVs) (Bartholoma¨us et al., 2009; Phillipson
et al., 2009), but the impact of flow on the migration of intralym-
phatic DCs remains unclear (Nitschke´ et al., 2012; Tal et al.,
2011). In agreement with our previous findings (Nitschke´ et al.,
2012), injection of PBS, to experimentally increase lymph flow,
did not alter the degree of downstream-directed migration (Fig-
ures 1C and 1D). To further investigate the potential contribution
of flow, we performed time-lapse imaging experiments in ear
skin explants that lack interstitial and intralymphatic flow. Upon
addition of YFP+ DCs to the dermal sides of ear tissue explants,
many DCs were observed crawling within LVs with morphologic
characteristics of capillaries (blind ends, wide, tortuous shape)
but also in vessels with a collector-like morphology (thinner
and more straight, presence of valves) (Figure 1E; Movies S4
and S5; Figure S1). Interestingly, even in explants DCs within
vessels with capillary-like morphology continued to migrate
semi-directedly in the downstream direction (Figures 1F and
1G). Conversely, in vessels with collector-like morphology, in
which DCs would typically flow in vivo, the DMI was reduced
to 0 (Figures 1F and 1G). These findings demonstrated that pref-
erential downstream migration of DCs within lymphatic capil-
laries did not require the presence of lymph flow and indicated1724 Cell Reports 14, 1723–1734, February 23, 2016 ª2016 The Auththat this behavior might depend on chemotactic signals depos-
ited within the capillary lumen.
CCL21 Is Present within Lymphatic Capillaries
Given the prominent role of CCL21 in DCmigration into LVs (Fo¨r-
ster et al., 1999; Saeki et al., 1999;Weber et al., 2013) and across
the subcapsular sinus into LNs (Ulvmar et al., 2014), we hypoth-
esized that this chemokine might also play a role in intralym-
phatic DC migration. This, however, implied that besides its
reported localization to the abluminal side of LVs (Weber et al.,
2013) and in large deposits within the LEC cell body (Vigl et al.,
2011; Weber et al., 2013), CCL21 would also be present in the
LV lumen. To investigate this, we performed high-resolution
confocal imaging in ear skin whole mounts under unfixed non-
permeabilizing conditions, which allowed us to only stain extra-
cellular but not intracellular CCL21 (Weber et al., 2013). This
analysis indeed detected CCL21 immunoreactivity within the
lumen of lymphatic capillaries (Figures 2A and 2B). Similarly,
immune-electron microscopy performed on human skin sec-
tions revealed CCL21-specific immunogold particles on the
luminal surface of dermal LECs, occasionally co-localizing with
podoplanin (Kerjaschki et al., 2004) (Figure 2C). Moreover,
ELISA-based quantification of CCR7 ligands detected high
levels of CCL21 and CCL19 in samples of human skin-draining
afferent lymph, but not in corresponding plasma samples (Fig-
ure 2D). Thus, our analyses confirmed the presence of CCL21
within LVs, suggesting that this chemokine could potentially be
involved in downstream-directed migration of DCs within
capillaries.
Interfering with CCR7/CCL21 Signaling Reduces
Downstream Migration of DCs in Lymphatic Capillaries
We therefore studied how treatment with CCL21-blocking anti-
body or control immunoglobulin G (IgG) affected the intralym-
phatic migration of adoptively transferred DCs. CCL21 blockade
had no effect on the migration speed (Figure 3A) but significantly
reduced the DMI and the percentage of DCs migrating in the
downstream direction within capillaries (Figures 3B and 3C).
We also quantified intralymphatic migration of adoptively trans-
ferredwild-type (WT) as compared to CCR7/DCs (Figures 3D–
3F). CCR7/ DCs have a reduced ability to enter into LVs (Tal
et al., 2011; Weber et al., 2013). However, when imaging 1 hr af-
ter injection, we typically found some intralymphatic CCR7/
DCs, which likely had been forced into the vessel by the injection.
Similarly to CCL21 blockade, the DMI of CCR7/ DCs ap-
proached a value of 0, indicative of random migration (Figures
3E and 3F). Notably, besides reducing the DMI, CCL21 blockade
or loss of CCR7 signaling also significantly reduced the chemo-
tactic index of intralymphatic DCs and also of DCs migrating in
the interstitium (data not shown). To investigate whether
blockade of CCL21/CCR7 signaling would similarly impact the
migration of endogenous DCs within lymphatic capillaries, we
performed IVM in bone marrow (BM) chimeras (CD11c-YFP/
VE-cadherin-Cre3RFP). In agreement with our previous results,
CCL21 blockade did not affect the speed but reduced the DMI of
endogenous DCs migrating within capillaries to approximately
0 (Figures 3G–3I). Similar findings were made when performing
IVM in BM chimeras or in WT mice treated with pertussis toxin,ors
Figure 1. Preferential Migration of DCs within Lymphatic Capillaries in the Downstream Direction Occurs Independently of Lymph Flow
(A) Confocal image from an IVM experiment showing YFP+ DCs patrolling within RFP+ lymphatic capillaries of a VE-cadherin-Cre3RFPmouse. The latter mouse
expresses red fluorescent protein (RFP) in all vessels, but LVs are easily distinguished from BVs based on morphological differences. Orthogonal views confirm
the intralymphatic location of selected DCs. BV, blood vessels; LV, lymphatic vessels. Scale bar, 50 mm. Image taken from Movie S3.
(B) Graphic scheme of DCs patrolling within lymphatic capillaries or flowing in a collector. Formula for the calculation of the downstream migration index (DMI).
OMP, optimal migratory path; TPL, total path length.
(C) DMI of adoptively transferred DCs migrating in lymphatic capillaries before or after PBS injection, to increase lymph flow.
(D) Color-coded percentages of DCs with positive or negative DMIs.
(E) Confocal images from ear explants of VE-cadherin-Cre 3 RFP mice showing YFP+ DCs crawling in the lumen of LVs with capillary-like or collector-like
morphology. Scale bar, 50 mm.
(F) DMI of DCs crawling in all LVs in capillary- or collector-like LVs of ear skin explants. Comparison to the DMI observed in IVM (C).
(G) Color-coded percentages of DCs with positive or negative DMIs.
Each dot in (C) and (F) represents one tracked cell. Pooled data from six (C and D) and five (F and G) different experiments per condition are shown.which blocksGai-protein-coupled receptor signaling (Figure S2).
To better understand why the DMI was reduced, we analyzed
how the different treatment conditions affected the turning
behavior of intralymphatic DCs. Blockade of CCL21/CCR7
signaling lead to intralymphatic DCs changing their migratory di-Cell Rrection more frequently (Figure S3). In conclusion, interfering
with CCL21 or CCR7 signaling reduced the ability of adoptively
transferred and of endogenous intralymphatic DCs to preferen-
tially migrate in the direction of the downstream collecting
vessels.eports 14, 1723–1734, February 23, 2016 ª2016 The Authors 1725
Figure 2. CCL21 Is Present within Lymphatic Capillaries
(A) Immunofluorescent whole-mount analysis of extracellular CCL21 performed in unfixed, non-permeabilized ear skin. Scale bar, 100 mm.
(B) High-magnification confocal image of CCL21 in a LYVE-1+ LV. Orthogonal views reveal intraluminal CCL21 (white arrows). Scale bar, 10 mm.
(C) Immunoelectron microscopic localization of CCL21 (10-nm gold particles, red arrowhead) on podoplanin-expressing (5-nm gold particles, blue arrowhead)
dermal LECs in human skin sections.
(D) ELISA-based quantification of CCL19 and CCL21 in human skin-draining afferent lymph and corresponding blood plasma samples (n = 3).Low Flow Establishes Concentrational Shifts of CCL21
along the Surface of In-Vitro-Cultured LEC Monolayers
Our findings suggested that CCL21 was present, although not
homogenously distributed, in the lumen of lymphatic capillaries
(Figure 2). Moreover, the overall preference of DCs to migrate
in the downstream direction suggested that higher CCL21 levels
might be present in the more downstream-located capillary seg-
ments. Notably, CCL21 contains a positively charged C-terminal
moiety that mediates its binding to negatively charged macro-
molecules, such as heparan sulfates (HS) in the extracellular
matrix or on cell surfaces (Bao et al., 2010; Weber et al., 2013).
We therefore hypothesized that the lymph flow conditions
present within lymphatic capillaries might contribute to the for-
mation of a downstream-oriented CCL21 gradient, by promoting
CCL21 dissociation from LECs in the initial capillary segments
and subsequent CCL21 rebinding to LECs located further
downstream (Figure S4A). To investigate and visualize the poten-
tial formation of a flow-induced CCL21 gradient, we performed
in vitro experiments with conditionally immortalized murine
LECs (imLECs) (Vigl et al., 2011). Since imLECs do not express
CCL21(Vigl et al., 2011), we used lentiviral vectors to generate1726 Cell Reports 14, 1723–1734, February 23, 2016 ª2016 The Authstable imLEC cell lines expressing either full-length CCL21 fused
to the fluorescent protein mCherry (CCL21-mCh), a CCL21-
mCherry fusion protein lacking CCL21’s positively charged
C terminus (CCL21DC-mCh), or imLECs expressing mCherry
(mCh) only (Figures S4B–S4F). To investigate whether flow could
establish a downstream-oriented CCL21 gradient on lymphatic
endothelium, we cultured confluent monolayers of CCL21-
mCh-expressing imLECs or mCh-expressing control imLECs
for 24 hr in the presence of low flow (0.015 dyn/cm2), to
mimic conditions in lymphatic capillaries (Berk et al., 1996;
Swartz et al., 1996). When subsequently analyzing the mCh
signal, we observed that the downstream regions of flow-
exposed imLEC monolayers expressing CCL21-mCH displayed
overall higher mCh signals than downstream regions of control
monolayers (Figures 4A and 4B). Notably, increasedmCh signals
in downstream regions of flow-exposed monolayers were only
observed with CCL21-mCH-expressing imLECs, but not when
exposing mCh-expressing control imLECs to flow (Figure S5).
Overall, these findings suggested a flow-induced shift of
CCL21 from upstream to downstream regions of the imLEC
monolayers.ors
Figure 3. Interfering with CCR7/CCL21 Signaling Reduces Down-
stream Migration of DCs within Lymphatic Capillaries
(A–F) Analysis of the intralymphatic speed and of the DMI of adoptively
transferred DCs. IVM-based quantification of DC migration within lymphatic
capillaries was performed (A–C) 4 hr after adoptive DC transfer and
anti-CCL21 treatment or (D–F) 1 hr after adoptive transfer of either WT or
CCR7/ DCs.
(G–I) Analysis of the speed and of the DMI of endogenous DCs: IVM was
performed in BM chimeric VE-cadherin-Cre 3 RFP mice that had been re-
constituted with BM of CD11c-YFP mice. Prior to IVM, DC migration was
induced in the ear skin of the chimeras by topical treatment with imiquimod
Cell RLow Flow Generates a Functional CCL21 Gradient along
the Surface of In-Vitro-Cultured LEC Monolayers
We next performed time-lapse imaging of DCs placed onto flow-
exposed or resting (no flow) imLECs, to investigate whether pre-
exposure to flowwas capable of establishing a functional CCL21
gradient along imLECsmonolayers. To quantify DC directionality
in the flow chamber setup, we devised a new parameter: the
in vitro DMI (ivDMI) is calculated by dividing the x axis compo-
nent of the cellular displacement by the TPL. In analogy to the
DMI, the ivDMI is assigned a positive or negative value, depend-
ing on which direction (i.e., with or against the applied flow) the
cell had migrated (Figure 4C). For DC migration experiments,
the three different imLEC cell lines were cultured for 24 hr in
the presence or absence of flow. DCs were subsequently added
onto themonolayers and their migration recorded in the absence
of flow. Analysis of the cell migration tracks revealed that DCs
placed onto flow-exposed CCL21-mCh-expressing monolayers
indeed displayed preferential migration in the downstreamdirec-
tion of flow (Figures 4D and 4E). By contrast, no downstream-
directed migration was observed on CCL21-mCh-expressing
monolayers cultured in the absence of flow, or when DCs were
placed onto flow-exposed monolayers expressing mCh only or
CCL21DC-mCh lacking the positively charged, LEC-binding C
terminus (Figures 4D and 4E). Similarly, when imaging the migra-
tion of WT and CCR7/ DCs on imLEC monolayers expressing
CCL21-mCh, preferential migration in the downstream direction
was only observed in WT but not in CCR7/ DCs migrating on
flow-exposed imLECs (Figures 4F and 4G). In conclusion, flow-
induced preferential migration in the downstream direction was
mediated by CCL21 and required the immobilization of CCL21
on the imLEC cell surface.
The Formation of a Functional CCL21 Is Shear Rate
Dependent
Intriguingly, we observed that the ability of flow to establish
a haptotactic CCL21 gradient along imLEC monolayers was
dependent on the shear strength applied: when performing DC
migration experiments on CCL21-mCh imLECs that had been
exposed to 100-fold higher shear rates (1.5 dyn/cm2), to mimic
shear rate conditions in BVs or in contracting lymphatic collec-
tors, preferential migration in the downstream direction of flow
was completely abolished (Figures 5A and 5B).
Immobilized CCL21 Accounts for Downstream
Migration in Capillaries of Skin Explants
With these results, we went back to the ear explant model to
investigate whether also in this setup, in absence of flow, DC
migration in the downstream direction was dependent on
CCL21/CCR7 signaling. Performing experiments with fluores-
cently labeled CCR7/ DCs, we observed that cell entry
into LVs was reduced, albeit still sufficient to analyze intralym-
phatic behavior of CCR7/ cells. Similarly to the in vivo
situation, we observed that only WT but not CCR7/ DCs pref-
erentially migrated in the downstream direction in vessels withand intradermal injection of LPS. Each dot represents one tracked cell. Pooled
data from six to nine different experiments per condition are shown.
(C, F, and I) Color-coded percentages of DCs with positive or negative DMIs.
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Figure 4. Flow Generates a Functional CCL21 Gradient on the Surface of In-Vitro-Cultured Murine LECs
(A and B) CCL21-mCh expressing imLECmonolayers were cultured 24 hr in absence (NO FLOW) or presence of low laminar flow (FLOW 0.015 dyn/cm2). mCh
and DAPI intensities were measured in two defined regions of the chamber. (A) Illustration of the experiment and representative images of the mCh signal (white).
(B) Quantification of mCh signal, normalized to DAPI (to account for potential differences in cell numbers) (n = 4 experiments).
(C) Schematic and mathematical explanation of the in vitro DMI.
(D) ivDMI of DCs crawling on flow-exposed or control-treated imLEC monolayers expressing mCh, CCL21-mCh, and CCL21DC-mCh.
(F) ivDMI of fluorescently labeled WT as compared to CCR7/ DCs crawling on flow-exposed (FLOW) or control (NO FLOW) imLEC monolayers expressing
CCL21-mCh. Each dot represents one tracked cell. Pooled data from three different experiments per condition are shown.
(E and G) Track plots from one out of three similar experiments. The central light green arrow indicates the overall migration directionality and represents the sum
of the displacement vectors of all tracked cells. The percentages of cells migrating in downstream or upstream direction are indicated below the horizontal green
or red arrows at the top.
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Figure 5. A Functional CCL21 Gradient For-
mation Is Induced under Low-Flow but Not
under High-Flow Conditions
CCL21-mCh expressing imLEC monolayers were
cultured 24 hr in absence (CONTROL) or
presence of low (0.015 dyn/cm2  13) or high
(1.5 dyn/cm2  1003) laminar flow, to mimic
conditions in lymphatic capillaries and blood
vessels, respectively. Subsequently, migration of
YFP+ DCs was quantified by performing time-
lapse imaging experiments.
(A) Analysis of the ivDMI. Each dot represents one
tracked cell. Pooled data from three different ex-
periments per condition are shown.
(B) Track plots from one out of three similar ex-
periments. In each plot, the central light green
arrow indicates the overall migration directionality
and represents the sum of the displacement vec-
tors of all tracked cells. The percentages of cells
displaying overall migration in downstream or
upstream direction is indicated below the hori-
zontal green or red arrows at the top.capillary-like morphology (Figures 6A and 6B). Neither WT nor
CCR7/ DCs migrated directedly in vessels with a collector-
like phenotype (Figures 6A and 6B), in agreement with our obser-
vation that CCL21 expression was reduced or absent in
lymphatic collectors (Figure S5). Overall, our findings confirmed
that CCR7 signaling but not lymph flow was responsible for
downstream migration of DCs within lymphatic capillaries.
Our in vitro flow chamber data had indicated that CCL21
needed to be immobilized on LECs via its positively charged C
terminus in order to mediate flow-induced downstream migra-
tion of DCs (Figures 4D and 4E). Since HS was previously shown
to account for the immobilization of CCL21 on and around
LECs (Bao et al., 2010; Weber et al., 2013; Yin et al., 2014), we
investigated its involvement in intralymphatic DC migration.
Therefore, we imaged DC migration within capillaries of ear
explants that had been pre-treated with heparitinases, thereby
abolishing co-localization of CCL21 with LVs (Weber et al.,
2013) (Figure 6C). Pre-treatment with heparitinases significantly
reduced the DMI, and the percentage of DCs migrating in the
downstream direction within capillary-like vessels of ear ex-
plants (Figures 6D and 6E). These findings indicated that HS
was important for immobilization of CCL21 on the luminal side
of lymphatic capillaries and for the establishment of the intralu-
minal gradient.
CCL21 Blockade Reduces Emigration of Intralymphatic
DCs from the Skin
Wenext investigated whether, besides reducing the DMI of intra-
lymphatic DCs (Figure 3), blockade of CCL21 would also affect
the overall ability of DCs within lymphatic capillaries to advance
through afferent LVs. We addressed this in the ear explant
setting, where we first allowed lipopolysaccharide (LPS)-
matured YFP+ DCs to migrate for 4 hr into the dermis and intoCell Rlymphatic capillaries. At this time point, 89% of all DCs within
the explant were present within lymphatic capillaries, with only
few DCs (11%) remaining in the interstitial tissue (Figures 7A
and 7B). Next, explants were treated with control- or CCL21-
blocking antibodies. When imaging 4 hr later (i.e., 8 hr after start-
ing the experiment), the percentage of lymphatic capillary area
covered by DCs was significantly reduced in the control group
but not in the CCL21-blocked setup, indicating that CCL21
blockade had interfered with the DCs’ ability to advance from
the capillaries into the collecting vessels (Figures 7C and 7D).
Previous studies have shown that the emigration of DCs out of
skin explants occurs through LVs (Gunn et al., 1999; Lukas
et al., 1996; Stoitzner et al., 1999). In a final experiment, we there-
fore investigated whether blockade of CCL21 would also impair
intralymphatic DCs in their overall ability to emigrate through the
lymphatic network into the culture medium. For this, we again al-
lowed YFP+ DCs to enter for 4 hr into lymphatic capillaries of ear
skin explants, to achieve a starting condition with approximately
90% of all YFP+ DCs within lymphatic capillaries (Figures 7A and
7B). Explants were then incubated in fresh medium containing
either control or CCL21-blocking antibodies and the number of
DCs that had emigrated into the culturemediumwas determined
24 hr later. This fluorescence-activated cell sorting (FACS)-
based quantification detected a significant reduction (30%,
p = 0.0014) in the number of DCs that had emigrated from
anti-CCL21-treated as compared to control-treated explants
(Figures 7E and 7F). Notably, confocal microscopy confirmed
that under both treatment conditions DCs remaining in the ex-
plants at the 24-hr time point continued to mainly localize within
LVs, indicating that DC emigration had primarily occurred via the
lymphatic route (Figure 7G). Thus, blockade of CCL21 had
reduced the ability of intralymphatic DCs to emigrate out of the
explanted skin through the lymphatic network.eports 14, 1723–1734, February 23, 2016 ª2016 The Authors 1729
Figure 6. CCL21/CCR7 Signaling Accounts
for Downstream Migration of DCs in Ear
Explants
(A and B) Analysis of WT or CCR7/ DCs crawling
in capillary- or collector-like LVs of ear skin ex-
plants. Analysis of the (A) DMI and (B) color-coded
percentages of DCs with positive or negative
DMIs.
(C–E) Impact of heparitinase (HSase) treatment or
treatment with control medium on DC migration
within capillaries of ear explants.
(C) Effect of heparitinase treatment on colocaliza-
tion of extracellular CCL21 with LYVE-1+ LVs.
Scale bars, 50 mm.
(D and E) Effect of pre-treatment of ear tissue with
heparitinase on the (D) DMI and (E) color-coded
percentages of DCs with positive or negative
DMIs.
Each dot in (A) and (D) represents one tracked cell.
Pooled data from five different experiments per
condition are shown (A and B, D and E).DISCUSSION
CCL21/CCR7 is widely recognized as the most important driver
of DC trafficking from peripheral tissues to dLNs (Fo¨rster et al.,
1999; Moussion and Girard, 2011; Ulvmar et al., 2014; Weber
et al., 2013). The profound impact of CCL21 on DC migration
has thus far mainly been attributed to its role in DC chemotaxis
toward LVs. However, CCL21 was recently shown to also
mediate subsequent steps in DC migration, such as the docking
and transmigration across the lymphatic endothelium as well as
DC transit across the LN subcapsular sinus (Johnson and Jack-
son, 2010; Tal et al., 2011; Ulvmar et al., 2014), indicating a more
complex role of this chemokine in lymphatic migration. In this
study, we report on yet another, rather unexpected mechanism
by which CCL21 promotes DC trafficking: it guides intralym-
phatic DCs from capillaries into collecting vessels and thereby
enables them to more efficiently advance through the lymphatic
network.1730 Cell Reports 14, 1723–1734, February 23, 2016 ª2016 The AuthorsLeukocyte crawling in lymphatic capil-
laries was only recently discovered
(Nitschke´ et al., 2012; Sen et al., 2010;
Tal et al., 2011), but leukocyte crawling
in BVs has been described and investi-
gated for much longer (Bartholoma¨us
et al., 2009; Geissmann et al., 2005; Phil-
lipson et al., 2006, 2009). While some of
the latter studies demonstrated a link
between blood flow and the direction
sensing of intravascular leukocytes (Bar-
tholoma¨us et al., 2009; Phillipson et al.,
2009), our time-lapse imaging experi-
ments in mice and skin explants did not
reveal any connection between the crawl-
ing directionality of intralymphatic DCs
and lymph flow directionality. These find-
ings were in agreement with our previous
studies (Nitschke´ et al., 2012) but inapparent conflict with another publication, in which intradermal
injection of PBS to experimentally increase lymph flow-induced
DCs to migrate more directedly, i.e., with a higher chemotactic
index, within LVs (Tal et al., 2011). However, since the latter study
did not evaluate whether directed migration was more pro-
nounced in the upstream or in the downstream direction, it is
hard to compare these results to the ones obtained in our study.
On the other hand, our findings demonstrate a strong depen-
dence of downstream-directed migration on the DC’s ability to
sense CCL21. At the same time, our flow chamber findings indi-
cated a role for lymph flow in establishing an intralymphatic
CCL21 gradient. Thus, although flow is not directly affecting
DC migration our data suggest that it indirectly guides down-
stream-directed migration, by contributing to the establishment
of an intraluminal CCL21 gradient.
Experimental flowmeasurements in LVs have indicated values
ranging from 1 to 30 mm/s in capillaries (Berk et al., 1996; Swartz
et al., 1996), whereas in large collectors peak velocities of
Figure 7. Blockade of CCL21 Prevents Emigration of Intralymphatic DCs from Ear Skin Explants
(A andB) YFP+ LPS-matured DCswere added onto the dermal aspects of ear skin explants of VE-cadherin-Cre3RFPmice, and their localization in the tissue and
within lymphatic capillaries was analyzed 4 hr later. (A) Representative confocal image of DCs within RFP+ capillaries. Scale bar, 100 mm. (B) Image-based
quantification of DCs within lymphatic capillaries and in the interstitium. Each dot represents one analyzed image. Pooled data from three similar experiments are
shown.
(C) Quantification of DCs in lymphatic capillaries at the 4-hr time point (4 hr) and after an additional 4 hr in presence of CCL21-blocking or control antibodies (8 hr).
(D) Each dot represents quantification of one field of view. Pooled data from three experiments are shown. Representative images taken at the 8-hr time point, i.e.,
4 hr after addition of antibodies. Scale bar, 100 mm.
(E and F) YFP+ LPS-maturedDCswere added onto the dermal aspects of ear skin explants and left to enter into LVs for 4 hr (as in A and B). Subsequently, explants
were incubated inmedia in presence of CCL21-blocking or control antibody, and the number of DCs that had emigrated into themediumwas quantified 24 hr later
by FACS. (E) Quantification of DCs in five individual experiments (connected by a line). Each experiment involved two to three explants/condition. (F) Summary of
the percentage reduction between control (100%) and CCL21-treated conditions in all experiments performed (n = 5).
(G) Representative images taken at the 24-hr time point. Scale bar, 200 mm.several millimeters per minute have been recorded (Dixon et al.,
2005). These measurements suggest that flow velocities and
shear rates in lymphatic capillaries are two to three orders of
magnitude lower than in postcapillary venules or in liver sinu-
soids, where intravascular leukocyte crawling has previously
been observed (Bartholoma¨us et al., 2009; Geissmann et al.,
2005; Phillipson et al., 2006). Interestingly, in our in vitro flow
chamber experiments CCL21 only established a functional,Cell Rdownstream-oriented gradient under low flow conditions
(0.015 dyn/cm2, corresponding to approximately 8 mm/s). Down-
stream-directed migration was completely abolished when
CCL21-mCh expressing imLEC monolayers had been pre-
cultured in presence of a 100-fold higher shear rate (1.5 dyn/
cm2), which more mimicked the flow conditions in BV capillaries
or peak flow conditions in lymphatic collectors. Thus, it is
possible that the high shear rates present in BVs or in lymphaticeports 14, 1723–1734, February 23, 2016 ª2016 The Authors 1731
collectors would not allow for the rebinding of chemokine in
downstream vessel segments and therefore not support the
establishment of a downstream-oriented intravascular gradient.
Overall, our findings suggest that the low flow present in
lymphatic capillaries and the constitutive expression of CCL21
by capillary LECs provide unique conditions that enable the for-
mation of a downstream-oriented gradient. Surprisingly, we
were not able to overwhelm the intralymphatic CCL21 gradient
when experimentally flooding the tissue with exogenous
CCL21: neither in the in vivo setup nor in ear skin explants did
administration/pretreatment with recombinant CCL21 lead to a
reduction in the DMI or in the chemotactic index of intralym-
phatic DCs (data not shown). However, we cannot exclude that
this failure to overwhelm the gradient was due to experimental
difficulties related to the chemokine dose or diffusion into the
vessel lumen.
Visualizing the intraluminal CCL21 gradient in vivo unfortu-
nately proved difficult, due to the strong CCL21 signal on
the abluminal aspect of the vessels and the rather weak and
patchy intraluminal signal. Interestingly, the staining performed
on imLEC monolayers also revealed a patchy distribution
pattern of CCL21 on the monolayer surface. Given our in vivo
and in vitro observations, it is perceivable that the presumed
intravascular CCL21 gradient within lymphatic capillaries is
rather heterogeneous. This could explain why DC migration
in capillaries occurs semi-directedly and involves frequent
directional turns. In fact, under all conditions investigated our
DMI analyses revealed that the downstream-directed compo-
nent of intralymphatic DC migration only corresponded to
approximately 15%–20% of the overall cellular movement;
i.e., DMIs typically ranged from 0.15 to 0.2. Yet blockade of
CCL21 or loss of CCR7 resulted in a complete loss of DC direc-
tionality within lymphatic capillaries (i.e., DMIs approaching a
value of 0). Moreover, CCL21 blockade functionally affected
the ability of DCs to emigrate from capillaries and out of the
skin through the dermal lymphatic network. Thus, although in-
tralymphatic migration in lymphatic capillaries occurs in a
semi-directed manner, this directional component is crucial
for the overall ability of DCs to advance through the lymphatic
network.
Interestingly, studies performed more than 15–20 years ago
in human or murine skin explants already reported that upon
explant culture endogenous DCs accumulated in LVs and
emigrated out of the skin through the lymphatic network
(Gunn et al., 1999; Lukas et al., 1996; Stoitzner et al., 1999).
Our findings explain how CCL21 contributes to advancing
DCs through capillaries in this setup. However, it might seem
puzzling that DCs in explanted skin even manage to advance
through collectors, in which we found DC migration to occur
completely randomly. This might be explained by the fact
that in our imaging experiments the DMI of DCs migrating in
collectors was typically only analyzed in the inter-valve seg-
ments, the so-called lymphangions. Although we frequently
observed DCs passing through valves in the downstream direc-
tion, this passage was only rarely observed in the opposite,
retrograde direction (data not shown). Thus, in the explant
setting, the presence of downstream-oriented valves likely
added an additional level of directedness to DC migration1732 Cell Reports 14, 1723–1734, February 23, 2016 ª2016 The Auththrough collectors. In vivo, in presence of flow, the contribution
of valves to directedness of passive DC movement through
collectors is expected to be even more profound: in the
living animal, lymphatic valves prevent fluid backflow and
thus enable the efficient transport of lymph-borne leukocytes
from one contracting lymphangion to the next (Dixon et al.,
2005).
Although our findings strongly suggest a role for flow in the
establishment of the CCL21 gradient present within lymphatic
capillaries, we cannot exclude that other factors might
contribute to this process. For example, it could be that CCL21
protein expression differences exist in lymphatic capillaries,
with LECs located more distantly from the blind ends producing
or secreting higher CCL21 levels. Interestingly, it has recently
been shown that DCs can proteolytically cleave off the positively
charged C terminus of CCL21 and convert it from a surface-
bound to a soluble form (Schumann et al., 2010). Given that
DC entry primarily occurs in the initial capillaries (Pflicke and
Sixt, 2009) it is perceivable that transmigrating DCs cleaving
off CCL21 from the LEC surface could preferentially reduce
CCL21 levels in the capillary tip regions, thereby creating a local
chemokine sink. Moreover, it is possible that local differences in
the expression or intraluminal localization of macromolecules
involved in CCL21 presentation, such as HS (Bao et al., 2010;
Weber et al., 2013; Yin et al., 2014) or podoplanin (Kerjaschki
et al., 2004), could contribute to the establishment of an intralym-
phatic gradient.
An unresolved question remaining is why DCs that have
arrived in collecting vessels do not continue to crawl but detach
to be transported by flow. Most likely, the increased flow in
collecting LVs generates hydrodynamic forces that no longer
support intraluminal crawling. Moreover, in agreement with a
previous study in human skin (Wick et al., 2008), our FACS and
immunofluorescence analyses revealed lower levels of CCL21
in collector LECs (colLECs) as compared to capillary LECs
(capLECs), that might facilitate detachment of DCs from the
colLEC surface and transition to a flowing mode. In the future,
it will be interesting to investigate whether CCL21 also accounts
for the capillary-to-collector transit of other lymph-borne leuko-
cyte subsets that reportedly depend on CCR7 for migration to
dLNs (Bromley et al., 2005, 2013; Debes et al., 2005; Menning
et al., 2007).
In conclusion, our results identify CCL21 as the key molecule
orchestrating intralymphatic DCmigration from capillaries to col-
lectors. Ultimately, this level of molecular and cellular insight into
the process of DC migration could be of therapeutic relevance,
for example, in the context of DC-based vaccines, where promo-
tion of CCR7 signaling is expected to increase the arrival of intra-
lymphatic DCs in the dLNs and thus the induction of adaptive
immunity.
EXPERIMENTAL PROCEDURES
Mouse Strains
Wild-type (WT) C57BL/6 mice were purchased from Janvier. CCR7/ (Fo¨rster
et al., 1999) and CD11c-YFP mice (Lindquist et al., 2004) were bred in our fa-
cility. VE-cadherin-Cre 3 RFP were generated as described (Luche et al.,
2007; Nitschke´ et al., 2012). All experiments were approved by the Cantonal
Veterinary Office Zurich.ors
Generation of Bone Marrow-Derived DCs
BM-DCs were generated from CD11c-YFP, WT, or CCR7/ mice by incuba-
tion of BM cells in granulocyte-macrophage colony-stimulating factor (GM-
CSF)-containing medium (see Supplemental Experimental Procedures)
(Nitschke´ et al., 2012).
Time-Lapse Imaging
For IVM, 0.5–1 3 106 LPS-activated BM-DCs in 10 ml of media were injected
into two to three regions in the ventral side of the mouse ear pinna of isoflur-
ane-anesthetized VE-Cadherin Cre 3 RFP mice, as previously described
(Nitschke´ et al., 2012). IVM was started 1–3 hr after injection. Alternatively,
IVMwas performed in BM chimeras, i.e., VE-Cadherin-Cre3RFPmice recon-
stituted with BM from CD11c-YFPmice (Nitschke´ et al., 2012). Ex vivo imaging
was performed in ear skin explants of VE-Cadherin Cre3RFPmice following a
protocol established in analogy to previous reports (Pflicke and Sixt, 2009;
Weber et al., 2013). Briefly, the dermal side of the explant was incubated for
30 min at 37C with fluorescent BM-DCs in media. DCs that had not entered
into the dermis were subsequently washed off, and the explant was incubated
for additional 2 hr in freshmedia. Imaging (IVMor explants) was performed on a
Zeiss LSM 710 inverted confocal microscope (Carl Zeiss), recording time-
lapse videos of 1 hr. At the end of all experiments, a tile scan of the lymphatic
vasculature surrounding the imaged areawas recorded, to provide information
about the lymphatic network architecture and the assumed direction of
drainage. All treatment protocols, imaging time points, and microscopy spec-
ifications are provided as Supplemental Experimental Procedures.
Emigration Experiments in Ear Skin Explants
See Supplemental Experimental Procedures.
Analysis of DC Motility
Videos were analyzed with IMARIS software (v.7.1.1, Bitplane). For semi-auto-
mated cell tracking, tracks were generated by an automatic algorithm and veri-
fied manually. Only tracks of cells recorded for >20 min and with a total path
length of >100 mm were included in the analysis. If a cell was arrested
>30 min at the beginning or at the end of its track, only the motile part of the
track was evaluated. If a cell stopped >30 min in the middle of its track, it
was excluded from the analysis. The same parameters were applied to the
tracking of cells in in vitro experiments. To calculate the downstreammigration
index (DMI), a combined algorithm for digitization of cell tracks and vessels us-
ing FIJI (ImageJ) and IMARIS was developed (see Supplemental Experimental
Procedures). Briefly, the algorithm generated a virtual track in the mid-line of
the LV, from which the optimal migratory path (OMP) was computed. The
DMI was obtained by dividing the OMP by the total path length the cell had
migrated. A positive or a negative value was subsequently manually assigned
to the DMI, depending on whether DC migration had occurred in the down-
stream or upstream direction of the LV tree, as judged from the tile scan anal-
ysis (see Supplemental Experimental Procedures). The DMI analysis was
performed in a blinded manner and offline, at the end of the experiment. In
cases where the direction of drainage could not be deducted form the tile
scan, cells were excluded from the DMI analysis. Similarly, the morphology-
based assignment of vessels into capillary-or collector-like morphology was
performed offline and in a blinded fashion.
imLECsCulture, Viral Transduction, andFlowChamberExperiments
Conditionally immortalized LECs (imLECs), expressing a heat-labile version of
the large T antigen, were isolated from the back skin of H-2Kb-tsA58 (immorto)
mice (Jat et al., 1991) as previously described (Vigl et al., 2011). Cell culture
conditions, the generation of stable imLEC transfectants expressing mCherry
(mCh), CCL21DC-mCh, or CCL21-mCh as well as the flow chamber
experiments performed are described in the Supplemental Experimental
Procedures.
Statistical Analysis
Results are presented as medians. Datasets were analyzed using the Mann-
Whitney test. Differences were considered statistically significant when
p < 0.05. Significant outliers, identified by Grubb’s test, were excluded. Statis-
tical analysis was performed with Prism 6 (GraphPad).Cell RSUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and five movies and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.01.048.
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